Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $23.67 Average PT from Brokerages

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) has been given an average rating of “Moderate Buy” by the five ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $23.6667.

Several equities analysts recently commented on KYTX shares. Wells Fargo & Company increased their target price on shares of Kyverna Therapeutics from $27.00 to $31.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. HC Wainwright raised their price objective on Kyverna Therapeutics from $10.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Monday. Finally, William Blair began coverage on Kyverna Therapeutics in a report on Wednesday, August 20th. They set an “outperform” rating for the company.

Kyverna Therapeutics Trading Up 9.4%

Shares of Kyverna Therapeutics stock opened at $7.83 on Wednesday. The firm has a market capitalization of $342.95 million, a PE ratio of -2.10 and a beta of 3.79. Kyverna Therapeutics has a 12 month low of $1.78 and a 12 month high of $8.45. The business’s 50-day moving average price is $6.35 and its 200-day moving average price is $4.32.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its earnings results on Wednesday, November 12th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.12. As a group, analysts predict that Kyverna Therapeutics will post -3.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KYTX. Public Employees Retirement System of Ohio purchased a new position in shares of Kyverna Therapeutics in the third quarter worth $28,000. Capital Advisors Inc. OK bought a new stake in Kyverna Therapeutics in the 3rd quarter worth $60,000. Phoenix Wealth Advisors purchased a new position in shares of Kyverna Therapeutics in the second quarter valued at about $32,000. Catalyst Funds Management Pty Ltd purchased a new position in shares of Kyverna Therapeutics in the second quarter valued at about $37,000. Finally, Ameriprise Financial Inc. bought a new position in shares of Kyverna Therapeutics during the third quarter valued at about $77,000. Institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.